<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS), there is a high prevalence of <z:hpo ids='HP_0001654'>valvular heart disease</z:hpo> which leads to increased risk of thrombo-embolic events, in particular, cerebrovascular events </plain></SENT>
<SENT sid="1" pm="."><plain>We present a patient with <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e>, previous <z:hpo ids='HP_0002625'>deep-vein thrombosis</z:hpo>, and <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> with positive <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and anticardiolipin antibodies </plain></SENT>
<SENT sid="2" pm="."><plain>Echocardiographic examination revealed mitral valve leaflet thickening and verrucous vegetations consistent with Libman-Sacks <z:hpo ids='HP_0100584'>endocarditis</z:hpo>, which is commonly associated with APS </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with combined Libman-Sacks <z:hpo ids='HP_0100584'>endocarditis</z:hpo> and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, anticoagulation therapy with <z:chebi fb="8" ids="10033">warfarin</z:chebi> is indicated due to high risk of valvular <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and subsequent embolization </plain></SENT>
</text></document>